Diversified Trust Co Sells 20,175 Shares of DexCom, Inc. (NASDAQ:DXCM)

Diversified Trust Co decreased its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 53.8% in the fourth quarter, HoldingsChannel reports. The fund owned 17,357 shares of the medical device company’s stock after selling 20,175 shares during the quarter. Diversified Trust Co’s holdings in DexCom were worth $1,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of DXCM. Sachetta LLC increased its position in DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after buying an additional 171 shares in the last quarter. Versant Capital Management Inc bought a new stake in DexCom during the 4th quarter worth approximately $25,000. Riverview Trust Co lifted its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after purchasing an additional 232 shares in the last quarter. RPg Family Wealth Advisory LLC purchased a new position in DexCom during the third quarter valued at approximately $57,000. Finally, Covestor Ltd boosted its position in shares of DexCom by 53.7% in the third quarter. Covestor Ltd now owns 959 shares of the medical device company’s stock worth $64,000 after purchasing an additional 335 shares during the period. 97.75% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Sanford C. Bernstein raised their price objective on shares of DexCom from $82.00 to $86.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. Raymond James lowered their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th. Leerink Partners cut their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the stock a “buy” rating in a report on Wednesday, December 11th. Finally, Royal Bank of Canada dropped their price target on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research note on Friday, October 25th. Seven research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $98.00.

DexCom Stock Performance

NASDAQ DXCM opened at $80.09 on Thursday. The company has a market cap of $31.28 billion, a P/E ratio of 47.96, a P/E/G ratio of 2.46 and a beta of 1.12. The business’s 50 day moving average price is $76.59 and its 200-day moving average price is $79.52. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of the company’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This represents a 5.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 0.30% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.